Outcomes4Me
Oncology Clinical Trial Finder
Breast Cancer
Location

Active, not recruiting • Phase III • Stage III, IV • HER2 negative • Medical Oncology • Post-Menopausal • Brain Metastases present • Interventional

The following is imported from ClinicalTrials.gov:

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standard of care single-agent chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine) in participants with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of systemic chemotherapy.

The primary objective of this study will assess the safety and efficacy of datopotamab deruxtecan (Dato-DXd) in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer who have been treated with one or two prior lines of systemic chemotherapy. The study will be stratified based on number of previous lines of chemotherapy (1 vs. 2), prior use of CDK4/6 inhibitors (Yes vs. no) and geographic region of participant (US/Canada/Europe vs. rest of world). This study aims to see if datopotamab deruxtecan allows patients to live longer without their breast cancer getting worse, or simply to live longer, compared to patients receiving standard of care chemotherapy. This study is also looking to see how the treatment and the breast cancer affects patients' quality of life.

Breast Cancer

Study Design
Study type:

Interventional

Estimated enrollment:

732 participant

Actual study start date:

October 18, 2021

Eligibility Criteria
Ages eligible for study:

18 - 999

Sexes eligible for study:

both


Arms and Intervention
  • Dato-DXd

  • Capecitabine

  • Gemcitabine

  • Eribulin

  • Vinorelbine

Trial Information at Site
Last Updated:
Trial Information
ClinicalTrial.gov ID:

Active, not recruiting

Estimated Enrollment:

732

Last Updated:

01/27/2024


Trial Sponsor

AstraZeneca

Study Location (278)

Research Site

Los Angeles, California, United States

Research Site

Boston, Massachusetts, United States

Research Site

Chuo-ku, Japan

Research Site

New York, New York, United States

Research Site

Portland, Oregon, United States

Research Site

Seoul, Korea, Republic of

Outcomes4Me

© 2024 Outcomes4Me Inc. All rights reserved.